Solara Q1 FY27 Results: Revenue ₹384 cr, PAT +55%

Key takeaway from the July 23 earnings call

Solara Active Pharma Sciences Limited (NSE: SOLARA) discussed its Q1 FY27 performance in an earnings conference call held on July 23, 2026. The quarter covered the period ended June 30, 2026. Management highlighted that the company delivered its highest EBITDA and profit after tax in the last 18 quarters. Reported numbers showed growth on a year-on-year basis across revenue, EBITDA, and PAT. The update also pointed to a sharp split in performance between the base business and the ibuprofen business. Alongside profitability, Solara flagged a reduction in net debt during the quarter. The company said the transcript of the call would be made available within a week on its website.

Q1 FY27: Revenue up 20%, EBITDA up 10%

Solara reported overall revenue of ₹384.3 crore for Q1 FY27, up 20% year-on-year. EBITDA came in at ₹63.5 crore, up 10% year-on-year. Profit after tax (PAT) was ₹16.3 crore, up 55% year-on-year. The company described these as the highest EBITDA and PAT delivered in 18 quarters. In addition to the earnings call commentary, the published financial highlights provided more granularity on total income, revenue from operations, and other income. Total income for the quarter was reported at ₹384.29 crore, up 20.04% year-on-year from ₹320.13 crore in Q1 FY26. Compared with Q4 FY26, total income fell 1.96% from ₹391.98 crore. Revenue from operations was ₹381.60 crore, up 19.57% year-on-year, and down 1.47% quarter-on-quarter from ₹387.29 crore.

Base business drove growth, despite cost pressures

Management separated the quarter into the base business and the ibuprofen business. Base business revenue was ₹307.7 crore in Q1 FY27, up 24% year-on-year. Gross margin was reported at ₹158 crore, up 10% year-on-year. Base business EBITDA stood at ₹72.2 crore, up 8% year-on-year, with management noting cost pressures linked to higher raw material costs.

This mix matters because the base business EBITDA (₹72.2 crore) was higher than overall EBITDA (₹63.5 crore), indicating that losses in ibuprofen weighed on consolidated profitability. The company’s disclosures also show that the base business contribution was large enough to push reported PAT to a multi-quarter high even with the drag.

Ibuprofen remained loss-making in Q1 FY27

Solara’s ibuprofen business was explicitly called out as a weak spot for the quarter. Ibuprofen revenue was ₹76.5 crore, but EBITDA was a loss of ₹8.7 crore. The ibuprofen EBITDA margin was reported at negative 12%. These figures explain the gap between base business EBITDA and overall EBITDA.

The company did not, in the provided text, outline a specific corrective action plan for ibuprofen within the quarter. But the disclosure of a negative margin and an EBITDA loss highlights that the segment continued to dilute consolidated performance in Q1 FY27.

Margins: EBITDA margin at 17%, up 80 bps QoQ

The quarter included a margin improvement indicator. Solara reported an EBITDA margin of 17%, with an improvement of 80 basis points quarter-on-quarter. While the company’s update includes quarter-on-quarter revenue declines, the margin improvement suggests better operating leverage or cost management in the period, even as management referenced raw material cost pressures. Because the ibuprofen business remained negative, the consolidated 17% EBITDA margin also reflects the stronger base business performance.

Balance sheet: Net debt reduced by ₹135 crore

Solara reported net debt reduction of ₹135 crore during the quarter. Separately, net debt as of June 30, 2026 was stated at ₹479.5 crore. The company also disclosed a net debt to EBITDA target of 1.7x by March 2027. In addition to debt reduction, the business highlights included the status of a rights issue. As of June 30, 2026, the company raised ₹442.73 crore out of a total rights issue size of ₹449.95 crore.

These balance sheet disclosures are relevant in a quarter where operating performance improved, because they show simultaneous progress on leverage metrics and funding actions.

Consolidated vs standalone: what the update shows

The published highlights included both consolidated and standalone snapshots. On a consolidated basis, net profit for Q1 FY27 was ₹16.31 crore, up 55.04% year-on-year from ₹10.52 crore in Q1 FY26. On a standalone basis, net profit for Q1 FY27 was reported at ₹16.99 crore, up 61.35% year-on-year from ₹10.53 crore. The release also included profit before tax figures, matching the consolidated PAT figure of ₹16.31 crore in the highlights.

The presence of both sets of numbers helps investors map performance across the group, but the key headline in the earnings call remained the consolidated revenue, EBITDA, and PAT growth.

Key numbers table: Q1 FY27 snapshot

Market impact: what the figures signal for investors

The Q1 FY27 data points to a quarter where headline profitability improved sharply, with PAT up 55% year-on-year and EBITDA at a reported high over the last 18 quarters. At the same time, revenue was slightly lower sequentially based on total income and revenue from operations, even as EBITDA margin improved by 80 basis points quarter-on-quarter to 17%. For investors, the divergence between base business EBITDA (₹72.2 crore) and consolidated EBITDA (₹63.5 crore) keeps attention on the ibuprofen segment, which reported a negative 12% EBITDA margin.

The balance sheet disclosures add another layer: net debt reduced by ₹135 crore in the quarter and stood at ₹479.5 crore as of June 30, 2026. The rights issue update, with ₹442.73 crore raised out of ₹449.95 crore by June 30, 2026, provides a funding context alongside debt reduction targets.

Analysis: why the base business performance matters

The base business delivered faster year-on-year revenue growth (24%) than the overall business (20%), showing that the core portfolio expanded even when ibuprofen remained loss-making. The base business EBITDA increase of 8% year-on-year, alongside management’s comment on raw material cost pressures, suggests that operational execution was strong enough to protect profitability.

But ibuprofen continued to reduce consolidated results, with EBITDA loss of ₹8.7 crore on ₹76.5 crore revenue and a reported negative 12% EBITDA margin. With consolidated EBITDA margin at 17% and improving sequentially, the quarter indicates a combination of better base business economics and a persistent drag from ibuprofen that still needs monitoring in subsequent quarters.

What management shared on disclosures and next steps

Solara said the board met on July 23, 2026 to approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company uploaded the audio recording of the earnings call to its website, and the transcript was expected to be available within a week. The recording includes management commentary and an analyst Q&A, according to the call note.

Conclusion

Solara’s Q1 FY27 update showed ₹384.3 crore revenue, ₹63.5 crore EBITDA, and ₹16.3 crore PAT, with the company reporting its highest EBITDA and PAT in 18 quarters. Base business growth remained the main support, while the ibuprofen segment reported an EBITDA loss and negative margin. The quarter also included a 17% EBITDA margin with an 80 bps sequential improvement and a ₹135 crore net debt reduction. Investors tracking the story will likely focus next on subsequent quarterly updates for ibuprofen profitability, progress on leverage targets, and follow-through after the July 23, 2026 earnings call transcript is published.